Treatment Outcomes and Molecular Prognostic Factors in TP53 Mutated Myeloid Neoplasms
TP53-mutated myeloid neoplasms encompass biologically heterogeneous disorders with frequent cytogenetic abnormalities and poor outcomes. In myelodysplastic neoplasms, TP53 allelic state contributes to clinical phenotype and prognosis. In acute myeloid leukemia (AML) and myelodysplastic syndromes with excess blasts, molecular similarities support studying TP53-associated disease across conventional diagnostic boundaries, although pooling lower-risk and advanced diseases can introduce important clinical heterogeneity. Available therapies improve remission in some patients without reliably producing durable disease control. In a pooled analysis of poor-risk cytogenetic AML with TP53 mutations, azacitidine plus venetoclax increased remission compared with azacitidine alone without a corresponding improvement in survival. A recent molecular analysis of the pivotal CPX-351 trial found that benefit was concentrated in AML with myelodysplasia-related mutations rather than TP53-mutated AML. Allogeneic hematopoietic cell transplantation (HCT) can provide prolonged survival in selected patients, but its outcome depends on biological and clinical context. Retrospective transplant data support integrating VAF and cytogenetics, whereas biological-assignment data in MDS suggest that some patients with TP53 mutations benefit from transplantation. the investigators sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure. Our purpose was hypothesis generation rather than causal ranking of regimens or derivation of a validated transplant-selection rule.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Thomas CLUZEAU
- Número de telefone: +33 0492039025
- E-mail: cluzeau.t@chu-nice.fr
Estude backup de contato
- Nome: Caroline Fileni
- E-mail: fileni.c@chu-nice.fr
Locais de estudo
-
-
Alpes Maritimes
-
Nice, Alpes Maritimes, França, 06000
- CHU de Nice
-
Contato:
- Thomas CLUZEAU
- Número de telefone: +33 0492039025
- E-mail: cluzeau.t@chu-nice.fr
-
Contato:
- Caroline Fileni
- E-mail: fileni.c@chu-nice.fr
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
TP53 mutated AML and HR-MDS patients
Descrição
Inclusion Criteria:
- TP53 mutated myeloid AML (> 20% blasts) or HR-SMD
- Age: Age ≥ 18 years
- Allo-HCT was permitted.
- Available NGS analysis at diagnosis
- TP53 VAF > 2%
- Myeloid sarcoma were permitted
- Patients received at least 1 treatment line
Exclusion Criteria:
- TP53 mutations class 1 or 2 or 3 (American College of Medical Genetic and Genomics
- Patients alive at the start of the study who did not receive study information or who objected to the collection of data
- TP53 CCUS or CHIP
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: RETROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
TP53 mutated myeloid neoplasms from Nice University Hospital
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
|
TP53 mutated myeloid neoplasms from Saint-Louis University Hospital
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Description of clinical outcomes according to treatment patterns
Prazo: Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027
|
We sought to describe treatment patterns in fonction of outcomes in a pooled TP53-associated clinical cohort |
Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
HCT as a time-dependent exposure.
Prazo: Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027
|
Description of transplanted patients to assess HCT as a time-dependent exposure. |
Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027
|
|
Pre-HCT TP53 variant allelic frequency (VAF)
Prazo: Baseline
|
Variant allelic fraquency of TP53 at diagnosis |
Baseline
|
|
Molecular prognostic
Prazo: Baseline
|
To explore survival impact of cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 26Hemato01
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .